Syndax Reports Preliminary 2025 Results With Revuforj Q4 Net Revenue Of $44M, Up 38% QoQ, $125M Full-Year Revenue, Niktimvo Full-Year Net Revenue Of $152M, And $394M Cash Supporting Path To Profitability

Syndax Pharmaceuticals Inc +5.32%

Syndax Pharmaceuticals Inc

SNDX

25.15

+5.32%

  • Approximately $44 million and $125 million in preliminary (unaudited) Revuforj® (revumenib) 4Q25 and full year 2025 net revenue, respectively –
  •  – Continued acceleration in demand following approval in R/R NPM1m AML, with an approximate 38% increase in Revuforj net revenue in 4Q25 vs. 3Q25 -
  •  – $56 million and $152 million in preliminary (unaudited) Niktimvo™ (axatilimab-csfr) 4Q25 and full year 2025 net revenue, respectively; Syndax will report its share of the Niktimvo net profit when it reports full year 2025 results –
  •  – Ended 2025 with approximately $394 million in cash, cash equivalents and marketable securities (unaudited); fully funded through profitability –
  •  – Syndax to present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 3:00 p.m. PT/ 6:00 p.m. ET.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.